NCT06868836 is a Phase 2 clinical trial of JS207 in Non-squamous Non-small Cell Lung Cancer, sponsored by Shanghai Junshi Bioscience Co., Ltd..

Who is sponsoring NCT06868836?

NCT06868836 is sponsored by Shanghai Junshi Bioscience Co., Ltd..

What drugs are being tested in NCT06868836?

Interventions in NCT06868836: JS207, Pemetrexed, Carboplatin or cisplatin.

What condition does NCT06868836 study?

NCT06868836 studies Non-squamous Non-small Cell Lung Cancer.

Is NCT06868836 still recruiting?

NCT06868836 is currently recruiting now. Last updated 27 June 2025.

Last reviewed 2025-06-27 · How we verify

NCT06868836

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer

Recruiting now Phase 2 Last updated 27 June 2025

What this trial tests

Phase 2 trial testing JS207 in Non-squamous Non-small Cell Lung Cancer in 42 participants. Currently enrolling.

Timeline

30 May 2025

Primary endpoint
30 September 2025

30 April 2027

Quick facts

Lead sponsor	Shanghai Junshi Bioscience Co., Ltd.
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	30 May 2025
Primary completion	30 September 2025
Estimated completion	30 April 2027
Sites	1 location across China

Drugs / interventions tested

JS207 — full drug profile →
Pemetrexed — full drug profile →
Carboplatin or cisplatin — full drug profile →

Conditions studied

Non-squamous Non-small Cell Lung Cancer — all drugs for Non-squamous Non-small Cell Lung Cancer →

Sponsor

Shanghai Junshi Bioscience Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Non-squamous Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study targets patients with advanced NSCLC driven with positive driver genes who have failed TKI treatment, enrolling 36-42 participants. Patients will receive JS207 (10 or 15 mg/kg, IV, d1) + pemetrexed (500 mg/m², IV, d1) + platinum-based chemotherapy (carboplatin AUC5 or cisplatin 75 mg/m², d1) every 3 weeks for 4 cycles. Afterward, JS207 and pemetrexed will continue as maintenance therapy until discontinuation criteria are met. The study aims to assess the safety, tolerability, and preliminary efficacy of JS207 combination therapy.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy.
Lv Y, Duan T, Song J, Liu S, et al · · 2026 · cited 1× · PMID 41625480 · DOI 10.34133/cancomm.0002

Verify or expand the search:

Other trials of JS207

Trials testing the same drug.

NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06969027 — JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC · Phase 2 · recruiting
NCT06954467 — JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma · Phase 2 · recruiting
NCT06885385 — A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Pa · Phase 2 · recruiting
NCT06944470 — JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC · Phase 2 · not yet recruiting

Other recruiting trials for Non-squamous Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT06627647 — A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non- · Phase 3 · recruiting

Other Shanghai Junshi Bioscience Co., Ltd. trials

Trials by the same sponsor.

NCT07503756 — JS212 Combination Therapies in Metastatic Colorectal Cancer · Phase 2 · not yet recruiting
NCT07480733 — Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting
NCT07484724 — A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Ce · Phase 2 · not yet recruiting
NCT07518160 — JS212 Plus JS111 in EGFR-Mutant Advanced NSCLC: A Phase II Study · Phase 2 · not yet recruiting
NCT07309276 — A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06868836 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Junshi Bioscience Co., Ltd.
Last refreshed: 27 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06868836.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing